Table 1 Baseline characteristics for eligible patients
Characteristic | Safety population (n = 50) | Efficacy population (n = 27) |
|---|---|---|
No (%) | No (%) | |
Sex | ||
 Female | 28 (56) | 12 (44) |
 Male | 22 (44) | 15 (56) |
Age, years, median (range) | 11 (3 - 18) | 11 (5-17) |
Diagnosis | ||
 Brain tumors | ||
  High-grade glioma | 19 (38) | 11 (41) |
  Medulloblastoma | 8 (16) | 4 (15) |
  Ependymoma | 3 (6) | 2 (7) |
  Low grade glioma | 2 (4) | 0 |
  PNET | 1 (2) | 1 (4) |
  Othera | 1 (2) | 1 (4) |
 Extracranial solid tumors | ||
  Ewing sarcoma | 4 (8) | 3 (11) |
  Osteosarcoma | 4 (8) | 2 (7) |
  Neuroblastoma | 2 (4) | 0 |
  DSRCT | 2 (4) | 1 (4) |
  Soft tissue sarcoma | 1 (2) | 1 (4) |
  Wilms tumor | 1 (2) | 0 |
  SETTLE tumor | 1 (2) | 1 (4) |
 Leukemia | ||
  AML | 1 (2) | 0 |
Lansky score | ||
 100 | 9 (18) | 5 (19) |
 90 | 13 (27) | 8 (30) |
 80 | 14 (29) | 11 (41) |
 70 | 6 (12) | 2 (7) |
 60 | 7 (14) | 1 (4) |
 Missing | 1 (2) | 0 |